List of Vaccines Companies in Connecticut - 4

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases.

L2 is a biotechnology company based in New Haven, Connecticut, USA with focus on new small molecule therapeutics, vaccines, and diagnostics

The SingleTimeMicroneedle Patch allows vaccines to be delivered via transdermal patch that painlessly embeds bodily degradable microneedles in the skin. The microneedles can be programmed for delivery over time and at specific times, requires no refrigeration, and can be self-administered by patients. The core technology of STM is a vaccine patch which can be painlessly applied at a single time on the skin to embed arrays of microneedles (MNs) inside the superficial skin layer (like an invisible tattoo). The MNs are made of a safe biodegradable polymer (used for surgical suture) and pre-programmed to release vaccines repeatedly over a long period, mimicking the effect of multiple prime/booster doses in the traditional vaccination process. The vaccines (including subunit protein-based antigen, vector-based vaccine or mRNAs) are stabilized against high temperatures, thus avoiding the need of cold-chain storage facilities and affirming the antigenicity for a long-term skin embedment. The technology will revolutionize the vaccination process by (1) enabling a high immunogenic efficacy via transdermal delivery, (2) enhancing patient compliance via the use of painless and self-administered skin patch, and (3) removing the logistic/economic burden to store vaccines at high temperatures. This skin patch could also be applied for animal vaccination, offering a high impact on both healthcare and other industry sectors.